A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.

Journal Article (Clinical Trial;Journal Article)

Nineteen patients with Raynaud's phenomenon in conjunction with progressive systemic sclerosis were given either prazosin hydrochloride (1 mg orally three times a day) or a placebo for eight weeks, after which the treatment procedure was reversed for four weeks. Prazosin was shown to be effective in reducing both the frequency and the severity of vasospasm reported by the patients.

Full Text

Duke Authors

Cited Authors

  • Surwit, RS; Gilgor, RS; Allen, LM; Duvic, M

Published Date

  • March 1, 1984

Published In

Volume / Issue

  • 120 / 3

Start / End Page

  • 329 - 331

PubMed ID

  • 6367665

International Standard Serial Number (ISSN)

  • 0003-987X


  • eng

Conference Location

  • United States